199 related articles for article (PubMed ID: 19231907)
21. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
23. Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV.
Barnett PG; Sorensen JL; Wong W; Haug NA; Hall SM
Drug Alcohol Depend; 2009 Feb; 100(1-2):115-21. PubMed ID: 19054631
[TBL] [Abstract][Full Text] [Related]
24. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study.
Ganguli A; Wang J; Gourley DR
Res Social Adm Pharm; 2012; 8(2):157-65. PubMed ID: 21712147
[TBL] [Abstract][Full Text] [Related]
25. Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system.
González Rivas L; Sánchez Gómez E; Sánchez del Moral R; Grutzmancher Saiz S; Pujol de la Llave E; Bocanegra Martín C
Farm Hosp; 2011; 35(6):317-21. PubMed ID: 22019116
[TBL] [Abstract][Full Text] [Related]
26. A comparative analysis of outpatient costs in HIV treatment programs.
Sarti FM; Nishijima M; Campino AC; Cyrillo DC
Rev Assoc Med Bras (1992); 2012; 58(5):561-7. PubMed ID: 23090227
[TBL] [Abstract][Full Text] [Related]
27. ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics.
Larson BA; Bii M; Henly-Thomas S; McCoy K; Sawe F; Shaffer D; Rosen S
J Int AIDS Soc; 2013 Jan; 16(1):18026. PubMed ID: 23305696
[TBL] [Abstract][Full Text] [Related]
28. The lifetime medical cost savings from preventing HIV in the United States.
Schackman BR; Fleishman JA; Su AE; Berkowitz BK; Moore RD; Walensky RP; Becker JE; Voss C; Paltiel AD; Weinstein MC; Freedberg KA; Gebo KA; Losina E
Med Care; 2015 Apr; 53(4):293-301. PubMed ID: 25710311
[TBL] [Abstract][Full Text] [Related]
29. Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial.
Charreau I; Jeanblanc G; Tangre P; Boyer L; Saouzanet M; Marchou B; Molina JM; Aboulker JP; Durand-Zaleski I;
J Acquir Immune Defic Syndr; 2008 Dec; 49(4):416-21. PubMed ID: 18931625
[TBL] [Abstract][Full Text] [Related]
30. [The pharmacoeconomics of antiretroviral drugs and the role of adherence].
Bargiacchi O; Brondolo R; Rizzo G; Garavelli PL
Infez Med; 2012 Dec; 20(4):245-50. PubMed ID: 23299063
[TBL] [Abstract][Full Text] [Related]
31. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda.
Babigumira JB; Castelnuovo B; Lamorde M; Kambugu A; Stergachis A; Easterbrook P; Garrison LP
BMC Health Serv Res; 2009 Oct; 9():192. PubMed ID: 19845963
[TBL] [Abstract][Full Text] [Related]
32. Adherence to antiretroviral therapy and associated factors among HIV positive adults attending care and treatment in University of Gondar Referral Hospital, Northwest Ethiopia.
Molla AA; Gelagay AA; Mekonnen HS; Teshome DF
BMC Infect Dis; 2018 Jun; 18(1):266. PubMed ID: 29879913
[TBL] [Abstract][Full Text] [Related]
33. Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging.
Andreu-Crespo À; Llibre JM; Cardona-Peitx G; Sala-Piñol F; Clotet B; Bonafont-Pujol X
Drug Des Devel Ther; 2015; 9():4287-90. PubMed ID: 26273190
[TBL] [Abstract][Full Text] [Related]
34. Adherence to Inhaled Medications and its Effect on Healthcare Utilization and Costs Among High-Grade Chronic Obstructive Pulmonary Disease Patients.
Kim JA; Lim MK; Kim K; Park J; Rhee CK
Clin Drug Investig; 2018 Apr; 38(4):333-340. PubMed ID: 29209982
[TBL] [Abstract][Full Text] [Related]
35. The cost of antiretroviral drugs and influence on prescribing policies.
Jones R; Gazzard B
Int J STD AIDS; 2006 Aug; 17(8):499-506. PubMed ID: 16925892
[TBL] [Abstract][Full Text] [Related]
36. Contemporary costs of HIV healthcare in the HAART era.
Gebo KA; Fleishman JA; Conviser R; Hellinger J; Hellinger FJ; Josephs JS; Keiser P; Gaist P; Moore RD;
AIDS; 2010 Nov; 24(17):2705-15. PubMed ID: 20859193
[TBL] [Abstract][Full Text] [Related]
37. [Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].
Kuhlmann A; Mittendorf T; Hower M; Heiken H; Gerschmann S; Klauke S; Lutz T; Bogner J; Degen O; van Lunzen J; Bachmann C; Stellbrink HJ; Schmidt W; Leistner I; Mahlich J; Ranneberg B; Stoll M
Gesundheitswesen; 2015 Jun; 77(6):e133-42. PubMed ID: 25247761
[TBL] [Abstract][Full Text] [Related]
38. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction.
Rwagitinywa J; Sommet A; Palmaro A; Montastruc JL; Lapeyre-Mestre M
Health Policy; 2018 Mar; 122(3):237-242. PubMed ID: 29398158
[TBL] [Abstract][Full Text] [Related]
39. Cost and cost-effectiveness of transitioning to universal initiation of lifelong antiretroviral therapy for all HIV-positive pregnant and breastfeeding women in Swaziland.
Cunnama L; Abrams EJ; Myer L; Gachuhi A; Dlamini N; Hlophe T; Kikuvi J; Langwenya N; Mthethwa S; Mudonhi D; Nhlabatsi B; Nuwagaba-Biribonwoha H; Okello V; Sahabo R; Zerbe A; Sinanovic E
Trop Med Int Health; 2018 Sep; 23(9):950-959. PubMed ID: 29956426
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
